Free tool
FAERS Monitor: Januvia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021995 or its brand name (Januvia, Sitagliptin Phosphate). Reports on generic versions are filed under their own applications.
Reports
72,446
Serious
46,797
65% of reports
Hospitalization
25,261
Death reported
6,838
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased4,520
- nausea3,964
- diarrhoea3,630
- drug ineffective3,575
- fatigue3,003
- headache2,582
- dizziness2,508
- vomiting2,462
- dyspnoea2,402
- acute kidney injury2,283
- pancreatitis2,231
- death2,218
- asthenia2,146
- malaise1,964
- weight decreased1,948
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 27 |
| 2007 | 3,569 |
| 2008 | 2,411 |
| 2009 | 2,444 |
| 2010 | 1,757 |
| 2011 | 1,967 |
| 2012 | 2,836 |
| 2013 | 3,661 |
| 2014 | 4,463 |
| 2015 | 6,599 |
| 2016 | 5,273 |
| 2017 | 4,741 |
| 2018 | 5,086 |
| 2019 | 5,057 |
| 2020 | 4,557 |
| 2021 | 3,805 |
| 2022 | 3,621 |
| 2023 | 2,891 |
| 2024 | 2,851 |
| 2025 | 2,804 |
| 2026 | 2,026 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,981,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancreatitisSignal | 2,231 | 12.8 | 12.2 | 23,191 |
| blood glucose increasedSignal | 4,520 | 7.1 | 6.9 | 23,374 |
| acute kidney injurySignal | 2,283 | 4.4 | 4.2 | 5,909 |
| weight decreasedSignal | 1,948 | 2.0 | 1.9 | 1,028 |
| asthenia | 2,146 | 1.7 | 1.6 | 570 |
| diarrhoea | 3,630 | 1.6 | 1.6 | 921 |
| vomiting | 2,462 | 1.5 | 1.5 | 449 |
| dizziness | 2,508 | 1.5 | 1.4 | 373 |
| nausea | 3,964 | 1.5 | 1.4 | 586 |
| malaise | 1,964 | 1.3 | 1.2 | 139 |
| dyspnoea | 2,402 | 1.2 | 1.2 | 108 |
| headache | 2,582 | 1.2 | 1.2 | 85 |
| fatigue | 3,003 | 1.1 | 1.1 | 40 |
| drug ineffective | 3,575 | 0.8 | 0.8 | 219 |
| death | 2,218 | 0.7 | 0.7 | 198 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.